Consequently, this compound as a therapeutic agent is a useful non-BBB permeable TPH1 inhibitor that can act on the peripheral system while preventing obesity and fatty liver disease. This evidence concerns the gene TPH1 and obesity due to melanocortin 4 receptor deficiency.